Arca
Skip to content

Rheumatoid arthritis

Drug research and approvals for rheumatoid arthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 297 studies of rheumatoid arthritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 58 drug trials for it since 2013, FDA has 5 approved and 12 open orphan designations naming it, and the EU has 41 authorised medicines for it.

  • Recruiting worldwide: 297
  • Trials authorized in Canada: 58
  • FDA orphan approvals: 5
  • EU medicines: 41

Recruiting Now

Newest start dates first, of 297 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 58; search them all in Canada trials
Nov 13, 2026A phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mk-8690 in participants with rheumatoid arthritisMK-8690Merck & Co. (MSD)Pending
Nov 7, 2025A multicentre, parallel-group, phase II, randomised, double-blind, 4 arm study to evaluate efficacy and safety of azd1163 in participants with moderately-to…AZD1163AstraZeneca Pharmaceuticals LPOngoing
Aug 22, 2025A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with rheumatoid arthritisTULISOKIBART (MK-7240)Merck & Co. (MSD)Ongoing
Aug 19, 2025A phase 2, multicenter, platform study of targeted therapies for the treatment of adult subjects with moderately to severely active rheumatoid arthritisLUTIKIZUMAB (ABT-981) / RAVAGALIMAB (ABBV-323)AbbVieOngoing
Dec 30, 2024Allogeneic hematopoietic cell transplantation for refractory rheumatoid arthritis - a pilot trialANTI-THYMOCYTE GLOBULIN / FLUDABARINE / CYCLOPHOSPHAMIDE / ALLOGENEIC…UNIVERSITY OF CALGARYPending
Sep 25, 2023A phase 2, randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study of sar441566 plus methotrexate in adults with…BALINATUNFIB (SAR441566)SANOFI-AVENTIS CANADA INCClosed
Jul 21, 2023A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rosnilimab in subjects with moderate to severe rheumatoid…ROSNILIMABANAPTYSBIO INCClosed
Jun 9, 2023A phase 1b, randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of imvotamab in…IGM-2323IGM BIOSCIENCES, INC.Pending
May 16, 2023A phase 3b/4 randomized, double-blind, double-dummy, active comparatorcontrolled study, comparing the efficacy and safety of upadacitinib versus adalimumab in…UPADACITINIB (ABT-494)/ ADALIMUMABAbbVieClosed
Apr 28, 2023Fecal microbial transplantation for rheumatoid arthritis: a proof of concept trial (femitra trial)FECAL MICROBIOTA TRANSPLANTATIONST JOSEPHS HEALTH CENTRE LONDONOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 17
Sep 30, 2014HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and…AbbVie Inc.Approved
May 9, 2013ILARISTreatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.Novartis Pharmaceuticals CorporationApproved
Feb 21, 2008HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and…AbbVie Inc.Approved
Aug 11, 2005MobicFor relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or…Avondale PharmaceuticalsApproved
May 27, 1999EnbrelReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and olderImmunex CorporationApproved
Jan 11, 2017protoplasmic protein matrix, omega-3 fatty oils, vitamins,…Treatment of juvenile rheumatoid arthritis.Leonard S. Girsh, MDDesignated
Apr 1, 2013Kre-CelazineTreatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric populationAll American Pharmaceutical & Natural Foods CorporDesignated
May 5, 2008nabumetoneTreatment of pediatric juvenile rheumatoid arthritisCook PharmaDesignated
Apr 4, 2005Interleukin-1 TrapTreatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's diseaseRegeneron Pharmaceuticals, Inc.Designated
Mar 16, 2004rofecoxibTreatment of juvenile rheumatoid arthritisMERCK & Co., Inc.Designated
May 25, 2001human gammaglobulinTreatment for juvenile rheumatoid arthritisLatona Life Sciences, Inc.Designated
Oct 14, 1998interferon Beta-1aTreatment of juvenile rheumatoid arthritis.Biogen, Inc.Designated
Feb 9, 1995Purified type II collagenTreatment of juvenile rheumatoid arthritis.AutoImmune, Inc.Designated
Jul 27, 1994Gammalinolenic acidTreatment of juvenile rheumatoid arthritis.Zurier, Robert B. M.D.Designated
Aug 23, 1993methotrexateTreatment of juvenile rheumatoid arthritis.Wyeth-Ayerst LaboratoriesDesignated

Medicines Authorised in the EU

Newest first; 15 of 41
Apr 27, 2026Tuyorytocilizumab · biosimilarChemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)EMA ↗
Apr 23, 2026Fubelvetanercept · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Feb 10, 2026Gotenfiagolimumab · biosimilarStada Arzneimittel AGEMA ↗
Nov 17, 2025Gobivazgolimumab · biosimilarAdvanz Pharma LimitedEMA ↗
Feb 14, 2025Avtozmatocilizumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗
Sep 19, 2024Ituxredirituximab · biosimilarReddy Holding GmbHEMA ↗
Jun 20, 2024Tosmova (previously Tocilizumab STADA and Tofidence)tocilizumab · biosimilarSTADA Arzneimittel AGEMA ↗
Sep 15, 2023Tyennetocilizumab · biosimilarFresenius Kabi Deutschland GmbHEMA ↗
Nov 15, 2021Hukyndraadalimumab · biosimilarStada Arzneimittel AGEMA ↗
Nov 12, 2021Libmyrisadalimumab · biosimilarStada Arzneimittel AGEMA ↗
Feb 11, 2021Yuflymaadalimumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗
Sep 24, 2020JyselecafilgotinibAlfasigma S.p.A.EMA ↗
May 20, 2020Nepextoetanercept · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Feb 13, 2020Amsparityadalimumab · biosimilarPfizer Europe MA EEIGEMA ↗
Dec 16, 2019RinvoqupadacitinibAbbVie Deutschland GmbH & Co. KGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.